Assignee
LYCERA CORP
US·24 granted patents·4 pending applications·87 citations·filing 2013–2020
Top patents by PatentIndex Score
28 records- 0194US9394315B2Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of diseaseLYCERA CORP·Filed 2013·Granted Jul 19, 2016·15 cites·30 claims
- 0292US9802958B2Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of diseaseLYCERA CORP·Filed 2016·Granted Oct 31, 2017·7 cites·25 claims
- 0391US10208061B2Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of diseaseLYCERA CORP·Filed 2017·Granted Feb 19, 2019·6 cites·19 claims
- 0489US9266839B2Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2014·Granted Feb 23, 2016·8 cites·53 claims
- 0588US9370507B2Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2015·Granted Jun 21, 2016·8 cites·27 claims
- 0687US9896441B2Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of diseaseLYCERA CORP·Filed 2015·Granted Feb 20, 2018·6 cites·58 claims
- 0786US9707211B2Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2016·Granted Jul 18, 2017·4 cites·30 claims
- 0885US9580388B2Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2015·Granted Feb 28, 2017·4 cites·27 claims
- 0984US9580391B2Saturated acyl guanidine for inhibition of F1F0-ATPaseLYCERA CORP·Filed 2013·Granted Feb 28, 2017·4 cites·30 claims
- 1084US9221814B2Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2013·Granted Dec 29, 2015·8 cites·28 claims
- 1180US10442798B2Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of diseaseLYCERA CORP·Filed 2018·Granted Oct 15, 2019·2 cites·30 claims
- 1280US10364237B2Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of diseaseLYCERA CORP·Filed 2017·Granted Jul 30, 2019·2 cites·20 claims
- 1379US10421751B2Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of diseaseLYCERA CORP·Filed 2016·Granted Sep 24, 2019·2 cites·26 claims
- 1477US10085972B2Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2017·Granted Oct 2, 2018·1 cites·31 claims
- 1575US10189777B2Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of diseaseLYCERA CORP·Filed 2015·Granted Jan 29, 2019·2 cites·24 claims
- 1675US9932313B2Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2017·Granted Apr 3, 2018·1 cites·25 claims
- 1773US10611740B2Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of diseaseLYCERA CORP·Filed 2016·Granted Apr 7, 2020·1 cites·44 claims
- 1873US10532088B2Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methodsLYCERA CORP·Filed 2015·Granted Jan 14, 2020·2 cites·37 claims
- 1971US9920012B2Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2013·Granted Mar 20, 2018·1 cites·27 claims
- 2071US9914706B2N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2014·Granted Mar 13, 2018·1 cites·26 claims
- 2169US10112935B2Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of diseaseLYCERA CORP·Filed 2016·Granted Oct 30, 2018·1 cites·32 claims
- 2268US9815791B2Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2014·Granted Nov 14, 2017·1 cites·28 claims
- 2361US2019175556A1Trifluoromethyl pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2018·Application pending·0 cites
- 2459US2018334438A1Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2018·Application pending·0 cites
- 2552US10392350B2N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereofLYCERA CORP·Filed 2018·Granted Aug 27, 2019·0 cites·21 claims
- 2651US10556898B2Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of diseaseLYCERA CORP·Filed 2019·Granted Feb 11, 2020·0 cites·31 claims
- 2746US2020207726A1Indolinyl sulfonamide and related compounds for use as agonists of rory and the treatment of diseaseLYCERA CORP·Filed 2019·Application pending·0 cites
- 2842US2020261463A1Treatment of cancer using aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide compoundsLYCERA CORP·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LYCERA CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →